Sistema de Información Esencial en Terapéutica y Salud


Última actualización: 5/8/2020
SIETES contiene 93082 citas

 1 a 18 de 18 
Presentar resultados
Seleccionar todas
3. Cita con resumen
Anónimo. Érythrodysesthésies palmoplantaires des antitumoraux anti-VEGF. Prescrire 2017;37:30-1. [Ref.ID 101368]
4. Cita con resumen
Anónimo. Cabozantinib. Prescrire 2015;35:650-3. [Ref.ID 99710]
7. Cita con resumen
Shah R, Morganroth J, Shah DR. Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives. Drug Saf 2013;36:491-503. [Ref.ID 95770]
Shah DR, Shah RR, Morganroth J. Tyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacy. Drug Saf 2013;36:413-26. [Ref.ID 95664]
Shah RR, Morganroth J, Shah DR. Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval). Drug Saf 2013;36:295-316. [Ref.ID 95517]
10.Enlace a cita original
Qi W-X, Shen Z, Lin F, Sun YJ, Min D-l, Tang LN, He A-N, Yao Y. Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials. Br J Clin Pharmacol 2013;75:919-30. [Ref.ID 95213]
11. Cita con resumen
Anónimo. Pour mieux soigner: des médicaments à écarter. Prescrire 2013;33:138-42. [Ref.ID 94882]
12. Cita con resumen
Bailey DG, Dresser G, Arnold MO. Grapefruit-medication interactions: forbidden fruit or avoidable consequences? . Can Med Assoc J 2013;185:309-16. [Ref.ID 94799]
13. Cita con resumen
Anónimo. Pamplemousses: des interactions avec les médicaments. Prescrire 2012;32:674-9. [Ref.ID 93661]
14. Cita con resumen
Anónimo. Vandetanib: risk of fatal outcome. Canada. WHO Drug Information 2012;26:112. [Ref.ID 93056]
15. Cita con resumen
Anónimo. Vandétanib. Trop dangereux dans les cancers médullaires de la thyroïde. Prescrire 2012;32:256-9. [Ref.ID 92578]
16. Cita con resumen
Anónimo. Vandetanib (Caprelsa) for medullary thyroid cancer. Med Lett Drugs Ther 2012;54:3. [Ref.ID 92102]
17. Cita con resumen
Chen P, Wang L, Liu B, Zhang HZ, Liu H-C, Zou Z. EGFR-targeted therapies combined with chemotherapy for treating advanced non-small-cell lung cancer: a meta-analysis. Eur J Clin Pharmacol 2011;67:235-43. [Ref.ID 90095]
18. Cita con resumen
Guha M. Mixed phase III results for Zactima in lung cancer. Scrip 2008;3417/18:6. [Ref.ID 84619]
Seleccionar todas
 1 a 18 de 18